GynOnc paper Review: SOLO-1 скачать в хорошем качестве

GynOnc paper Review: SOLO-1

Gyn Onc Paper Review SOLO-1. The focus of the paper was the administration of maintenance PAPR inhibitor (Olaparib) to patients who were BRCA positive and had a new diagnosis of advanced-stage ovarian cancer. Olaparib significantly increased progression-free survival and overall survival. SOLO-1 is a clinical trial in gynecologic oncology that investigated the use of the PARP inhibitor olaparib in the first-line treatment of women with advanced ovarian cancer who carry BRCA mutations. PARP inhibitors are a type of targeted therapy that work by blocking an enzyme called poly(ADP-ribose) polymerase (PARP), which is involved in repairing damaged DNA. By inhibiting PARP, cancer cells are prevented from repairing their DNA, which can lead to cell death. In the SOLO-1 trial, women with advanced ovarian cancer who carried BRCA mutations were randomized to receive either olaparib or placebo following primary debulking surgery (PDS) and platinum-based chemotherapy. The trial aimed to determine if the addition of olaparib improved progression-free survival (PFS) in this patient population. The results of the SOLO-1 trial showed that women who received olaparib had a significantly longer PFS compared to those who received placebo. Additionally, overall survival (OS) and time to first subsequent therapy (TFST) were also significantly improved in the olaparib group. These results led to the approval of olaparib for the maintenance treatment of advanced ovarian cancer in women who carry BRCA mutations. The findings of the SOLO-1 trial have important implications for the treatment of advanced ovarian cancer, particularly for women with BRCA mutations. The trial demonstrated that maintenance therapy with olaparib following PDS and chemotherapy can improve outcomes in this patient population. The success of SOLO-1 has also spurred further research into the use of PARP inhibitors in the treatment of ovarian cancer, including in combination with other therapies and in other patient populations. Moore et al., (2018): https://www.nejm.org/doi/full/10.1056... METHODS We conducted an international, randomized, double-blind, phase 3 trial to evaluate the efficacy of olaparib as maintenance therapy in patients with newly diagnosed advanced (International Federation of Gynecology and Obstetrics stage III or IV) high-grade serous or endometrioid ovarian cancer, primary peritoneal cancer, or fallopian-tube cancer (or a combination thereof) with a mutation in BRCA1, BRCA2, or both (BRCA1/2) who had a complete or partial clinical response after platinum-based chemotherapy. The patients were randomly assigned, in a 2:1 ratio, to receive olaparib tablets (300 mg twice daily) or placebo. The primary end point was progression-free survival. CONCLUSIONS The use of maintenance therapy with olaparib provided a substantial benefit with regard to progression-free survival among women with newly diagnosed advanced ovarian cancer and a BRCA1/2 mutation, with a 70% lower risk of disease progression or death with olaparib than with placebo. (Funded by AstraZeneca and Merck; SOLO1 ClinicalTrials.gov number, NCT01844986. opens in new tab.)